Literature DB >> 12763276

Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients.

Birgül Vanizor Kural1, Asim Orem, Gülseren Cimşit, Hüseyin Avni Uydu, Yunus Emre Yandi, Ahmet Alver.   

Abstract

BACKGROUND: Hyperhomocysteinemia may constitute an independent risk factor for cardiovascular disease and may promote atherothrombosis. Psoriasis is one of the diseases associated with increased atherothrombosis. The aim of the present study was to examine serum total homocysteine (tHcy) level and its relationships with atherothrombotic markers.
METHODS: The study group included 30 patients with psoriasis (17 females and 13 males) with a mean age of 34.2 (age range: 27-40) and 30 sex and age matched healthy volunteers (15 females and 15 males) with a mean age of 36.7 (age range: 26-48). The concentrations of lipids, lipoproteins, acute phase reactants, tHcy and atherothrombotic markers [fibronectin, soluble vascular adhesion molecules-1 (sVCAM-1), soluble intercellular adhesion molecules-1 (sICAM-1), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), autoantibodies against oxidized LDL (AuAb-oxLDL)] were determined.
RESULTS: The mean levels of serum tHcy, fibrinogen, fibronectin, sICAM, PAI-1 and AuAb-oxLDL were increased in patients whereas tPA, vitamin B(12) and folate levels were decreased significantly. Increased levels of sVCAM were not statistically significant. tHcy levels were negatively correlated with vitamin B(12) (r=-0.40, P=0.027) and positively correlated with PAI-1 and AuAb-oxLDL levels (r=0.46, P=0.011; r=0.39, P=0.035, respectively).
CONCLUSIONS: It was concluded that the increased homocysteine concentration and altered endothelial cell-mediated proteins associated with increased lipids and LDL oxidation may play an important role for the development of atherothrombotic complications with psoriasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763276     DOI: 10.1016/s0009-8981(03)00082-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  27 in total

1.  Methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis.

Authors:  Ercan Karabacak; Ersin Aydin; Omer Ozcan; Bilal Dogan; Mustafa Gultepe; Alpaslan Cosar; Tuba Muftuoglu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

2.  Immediate and long-term high levels of plasma homocysteine after extracorporeal shock wave lithotripsy in patients with renal stone disease.

Authors:  Erkan Demir; Volkan Izol; I Atilla Aridogan; Saime Paydas; Zuhtu Tansug; Ugur Erken
Journal:  Clin Exp Nephrol       Date:  2014-05-28       Impact factor: 2.801

3.  Homocysteine-reducing B vitamins and ischemic heart disease: a separate-sample Mendelian randomization analysis.

Authors:  J V Zhao; C M Schooling
Journal:  Eur J Clin Nutr       Date:  2016-11-30       Impact factor: 4.016

4.  Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis.

Authors:  Rui Vilar; Samuel W Lukowski; Marco Garieri; Corinne Di Sanza; Marguerite Neerman-Arbez; Richard J Fish
Journal:  Thromb Haemost       Date:  2020-12-10       Impact factor: 5.249

5.  Plasma homocysteine levels in multiple sclerosis.

Authors:  G S M Ramsaransing; M R Fokkema; A Teelken; A V Arutjunyan; M Koch; J De Keyser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

Review 6.  Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature.

Authors:  Rita V Patel; Michael L Shelling; Srdjan Prodanovich; Daniel G Federman; Robert S Kirsner
Journal:  J Gen Intern Med       Date:  2011-04-07       Impact factor: 5.128

Review 7.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

8.  MTHFR (methylenetetrahydrofolate reductase) C677T polymorphism and psoriasis.

Authors:  Vladimir Vasku; Julie Bienertova-Vasku; Miroslav Necas; Anna Vasku
Journal:  Clin Exp Med       Date:  2009-05-30       Impact factor: 3.984

9.  Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.

Authors:  Guilherme Gomes Teixeira; Naiara Lourenço Mari; Jaqueline Costa Castardo de Paula; Camila Cataldi de Alcantara; Tamires Flauzino; Marcell Alysson Batisti Lozovoy; Ligia Márcia Mário Martin; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi; Andréa Name Colado Simão
Journal:  Clin Exp Med       Date:  2019-11-22       Impact factor: 3.984

10.  Psoriasis and increased prevalence of hypertension and diabetes mellitus.

Authors:  Maryam Ghiasi; Mohammad Nouri; Ata Abbasi; Parvaneh Hatami; Mohammad Amin Abbasi; Keramat Nourijelyani
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.